Fox Run Management L.L.C. Invests $877,000 in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Fox Run Management L.L.C. bought a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,070 shares of the medical instruments supplier's stock, valued at approximately $877,000.

A number of other large investors have also added to or reduced their stakes in the company. NewSquare Capital LLC purchased a new position in shares of Merit Medical Systems in the fourth quarter valued at $32,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter worth about $52,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Merit Medical Systems during the 3rd quarter valued at about $120,000. Smartleaf Asset Management LLC raised its position in shares of Merit Medical Systems by 237.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier's stock valued at $134,000 after buying an additional 977 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Merit Medical Systems by 14.7% in the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier's stock valued at $144,000 after acquiring an additional 191 shares during the last quarter. Institutional investors own 99.66% of the company's stock.

Insider Transactions at Merit Medical Systems

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 31,320 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the completion of the sale, the chief executive officer now owns 1,086,028 shares in the company, valued at $112,794,868.08. This represents a 2.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephen C. Evans sold 5,000 shares of Merit Medical Systems stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the transaction, the director now owns 4,657 shares in the company, valued at $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,132 shares of company stock valued at $11,139,521. 3.70% of the stock is currently owned by corporate insiders.

Remove Ads

Merit Medical Systems Trading Down 0.4 %

Shares of NASDAQ:MMSI traded down $0.43 during trading on Thursday, reaching $103.27. 321,419 shares of the company were exchanged, compared to its average volume of 424,669. The business's fifty day simple moving average is $104.25 and its 200-day simple moving average is $100.94. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. Merit Medical Systems, Inc. has a 12-month low of $70.70 and a 12-month high of $111.45. The firm has a market capitalization of $6.08 billion, a PE ratio of 50.62, a P/E/G ratio of 2.34 and a beta of 0.91.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MMSI shares. Canaccord Genuity Group decreased their price objective on Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Barrington Research lowered their price target on Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC dropped their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company reduced their target price on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Raymond James lifted their price target on shares of Merit Medical Systems from $105.00 to $110.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 31st. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $110.78.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.